BACKGROUND: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. METHODS: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. RESULTS: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. CONCLUSIONS: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
BACKGROUND: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. METHODS: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. RESULTS: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. CONCLUSIONS: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
Authors: M Cobo-Dols; S Gil-Calle; E Villar-Chamorro; I Alés-Díaz; F Carabantes-Ocón; J Alcalde-García; V Gutiérrez-Calderón; A Montesa-Pino; J J Bretón-García; M Benavides-Orgaz Journal: Clin Transl Oncol Date: 2006-07 Impact factor: 3.405